Body Protection Compound-157 (Stable Gastric Pentadecapeptide)
A 15-amino acid peptide derived from human gastric juice that promotes mucosal integrity, tissue healing, and has demonstrated broad protective effects across multiple organ systems in preclinical studies.
BPC-157 helps your body heal faster by increasing blood flow to damaged areas (growing new blood vessels), boosting growth factor receptors, and reducing inflammation. It works on multiple repair pathways simultaneously, which is why it helps with so many different types of injuries. It also has protective effects on the brain and gut lining.
Primary use case. Extensive preclinical data showing accelerated healing of muscle, tendon, ligament, bone, and skin injuries. One human retrospective study showed pain relief in knee injuries.
Strong preclinical evidence for joint tissue repair and protection. Intraarticular injection studied for knee pain with positive results (7/12 patients, >6 month relief).
BPC-157 is derived from gastric juice and has extensive data on gut protection. Preclinical models show protection against NSAID-induced ulcers, inflammatory bowel disease models, and leaky gut. Oral dosing is viable due to gastric stability.
Promotes tissue repair and reduces inflammation, which are relevant to aging. Not a primary anti-aging peptide but contributes to overall tissue maintenance.
Upregulates GHR expression but is not a growth promoter. Better characterized as a healing/recovery peptide than a muscle-building one.
Neuroprotective effects demonstrated in preclinical models. Modulates dopamine and serotonin systems. Some preclinical data on counteracting Parkinson's and Alzheimer's-like disturbances. No human cognitive data.
Modulates inflammatory cytokines but is not primarily an immune peptide.
Not relevant to fat loss.
Not relevant to sleep.
Not relevant to sexual health.
BPC-157 positively interacts with the nitric oxide (NO) system, modulating NOS expression to produce context-dependent effects on NO levels. It upregulates VEGF and VEGF receptor expression, promoting angiogenesis and new blood vessel formation critical for tissue repair. The peptide enhances growth hormone receptor (GHR) expression and activates pathways involved in cell growth including FAK-paxillin and JAK-2/STAT-3. It reduces pro-inflammatory cytokines (TNF-alpha, IL-6) while counteracting free radical formation through increased heme oxygenase (HO-1) expression. BPC-157 also modulates dopamine and serotonin systems, providing neuroprotective effects.
Most common community protocol. Inject as close to the injury site as practical. 250mcg is the typical starting dose, 500mcg for more serious injuries.
BPC-157 is uniquely stable in gastric acid, making oral dosing viable. Community reports suggest oral route is particularly effective for GI issues but may also provide systemic benefits.
Higher dose protocol used in community for significant injuries. Limited dosing data in humans -- community-derived protocol.
The 2025 literature and patent review (PMID 40005999) notes that 'only a few side effects have been reported following its administration.' The IV safety pilot (PMID 40131143) found no measurable effects on heart, liver, kidney, thyroid, or blood glucose biomarkers at doses up to 20mg IV. Preclinical safety studies showed no adverse effects across several organ systems. However, clinical safety data remains extremely limited.
BPC-157 promotes angiogenesis and cell growth via VEGF and GHR upregulation. Theoretically could promote tumor growth or vascularization. No direct evidence of this, but the mechanism warrants extreme caution.
No safety data in pregnant or lactating women. Effects on fetal development unknown.
BPC-157 affects the NO system and angiogenesis, which could theoretically interact with blood clotting pathways.
BPC-157 modulates immune function and inflammatory pathways. May interact with immunosuppressive therapy.
No safety data in pediatric populations. Growth factor modulation could affect development.
Anti-inflammatory effects demonstrated in multiple preclinical models
Upregulates growth hormone receptor expression
Direct stimulation of VEGF and VEGF receptor expression is a primary mechanism
Reduces pro-inflammatory cytokines in preclinical models
Context-dependent modulation -- increases or decreases NO as needed for homeostasis
Hepatoprotective effects shown in preclinical models of liver damage. IV pilot showed no effect on liver markers in healthy subjects.
The most popular peptide stack. BPC-157 and TB-500 work through complementary healing mechanisms. BPC-157 promotes angiogenesis while TB-500 promotes cell migration and tissue repair. Commonly run together for injury recovery.
Both promote tissue repair through different pathways. GHK-Cu adds collagen synthesis and antioxidant benefits. Often stacked for skin/wound healing.
No known interactions. Some users stack for combined healing and growth hormone benefits.
No known interactions. Different mechanisms and targets.
No known interactions. Different immune modulation pathways.
Lee E, Burgess K - Altern Ther Health Med (2025) - Pilot study (human) - n=2
IV infusion of 10mg and 20mg BPC-157 was well-tolerated with no adverse effects. No measurable effects on biomarkers of heart, liver, kidneys, thyroid, or blood glucose.
Limitations: Extremely small sample size (n=2). Both participants had prior BPC-157 exposure. Short observation period (3 days). Single clinic, not blinded.
Vasireddi N, Hahamyan H, Salata MJ, et al. - HSS J (2025) - Systematic review
Reviewed 36 studies (35 preclinical, 1 clinical). BPC-157 enhances GHR expression, VEGF, angiogenesis, and reduces inflammatory cytokines. Improved outcomes in muscle, tendon, ligament, and bone injuries in preclinical models. Half-life less than 30 minutes. Metabolized in liver, cleared by kidneys.
Limitations: Almost entirely preclinical data. Only 1 human study included (retrospective, n=12). Level IV and V evidence only.
Jozwiak M, Bauer M, Kamysz W, Kleczkowska P - Pharmaceuticals (Basel) (2025) - Literature and patent review
Comprehensive review of BPC-157 biological activities, mechanism of action, and safety. Notes desirable safety profile with few reported side effects. Documents patent landscape showing commercial interest. WADA temporary ban in 2022 (subsequently removed).
Limitations: Review article, no new primary data.
Mayfield CK, Bolia IK, et al. - Am J Sports Med (2026) - Review
Comprehensive review of injectable peptide therapy including BPC-157, TB-4, TB-500, CJC-1295/Ipamorelin. Provides overview for clinicians considering peptide therapy.
Limitations: Review article for clinical audience.
Rahman OF, Lee SJ, Seeds WA - J Am Acad Orthop Surg Glob Res Rev (2026) - Review
BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation for wound healing.
Limitations: Review article.
BPC-157 is the most discussed peptide on r/Peptides (230K+ members). Community consensus: highly effective for tendon, ligament, and muscle injuries when injected near the injury site. Oral dosing widely reported as effective for gut issues (IBS, ulcers, acid reflux). Common protocol is 250-500mcg subQ 2x daily for 4-8 weeks. Often stacked with TB-500 for enhanced healing. Primary concerns: FDA compounding ban (Oct 2023) means sourcing shifted entirely to research chemical vendors, raising quality control concerns. Users recommend Janoshik-tested vendors. Most commonly reported side effects: mild injection site irritation, occasional nausea. The peptide community generally considers BPC-157 to have the best risk/reward ratio of any research peptide.
Research chemical. Banned from compounding pharmacies by FDA (October 2023). Not FDA-approved for any indication.
FDA issued a notice in October 2023 prohibiting compounding pharmacies from making BPC-157, classifying it as a substance that cannot be compounded under Section 503A or 503B. It remains available from research chemical vendors. WADA temporarily banned it in 2022 but it is not currently listed as prohibited. Athletes in tested sports should verify current status with their organization.
Extensive preclinical data (100+ animal studies over 30 years), but very limited human data. One IV safety pilot study (n=2), one retrospective knee pain study (n=12). No randomized controlled trials in humans.
Disclaimer: This information is for educational and research purposes only. PepStack does not provide medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider before using any peptide or supplement. Research suggests these compounds may have various effects, but individual results vary and many claims require further clinical validation.